uniQure reports FY2022 net loss of $126.8M; revenue drops to $106.5M from $524M

uniQure N.V.

2022-FY EPS reported -$2.71 revenue$106,483,000

Net loss of $126.8M ($2.71 loss per share) vs net income of $329.6M in 2021.
Revenue of $106.5M, down 80% YoY, primarily due to absence of large license revenue from CSL Behring transaction.
Cash and investments $392.8M as of Dec 31, 2022; expects funding into 2025 assuming $100M milestone from HEMGENIX first U.S. sale.
HEMGENIX received U.S. and EU marketing approvals for hemophilia B; eligible for $100M and $75M milestone payments from CSL Behring.
Pipeline: AMT-130 Huntington's update expected Q2 2023; AMT-162 (SOD1 ALS) and AMT-260 (epilepsy) Phase I/II trials expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

uniQure N.V. reported financial results for the full year ended December 31, 2022.

Period: the full year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 27, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2022 and highlighting company progress.

View on SEC.gov

Browse all earnings releases →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001104659-23-026119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.